PubMed Central
Cure8 research brief
Why This Matters
IBD can be linked to mood symptoms and treatment-resistant inflammation; an oral nanotherapy that targets the inflamed colon and the microbiota–gut–brain axis could potentially address both gut inflammation and associated anxiety/depression if later validated in humans.
Who Should Pay Attention
Researchers, clinicians treating IBD, patients with ulcerative colitis interested in experimental therapies, and those following microbiome/gut–brain axis research.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthMetadata only
What To Know
This paper reports development and preclinical testing of an oral nanotherapy (βG@Apr‑WPG nanomicelles) that delivers apremilast to the inflamed colon, alters gut microbiota, reduces intestinal and systemic inflammation, and improved anxiety- and depression-like behaviors in a mouse colitis model.
The authors describe formulation features (β‑glucan armor, tryptophan‑PLGA‑glutathione nanomicelles) intended to protect the drug through the stomach, increase colonic retention, and provide inflammation‑responsive release.
In the reported experiments, treated mice showed improved gut barrier integrity, reduced histologic damage, changes in microbiota composition, and reductions in markers of systemic and neuroinflammation compared with free apremilast.
These results are preclinical (mouse) data testing an investigational nanomedicine platform incorporating apremilast; they do not establish safety or efficacy in humans. If you have IBD or mood symptoms, this is not clinical advice—discuss treatment options with your care team.
Keep In Mind
Findings are from mouse models and an investigational nanomedicine formulation; human clinical trials would be required to determine safety and efficacy. The article reports preclinical mechanistic and efficacy data, not clinical outcomes.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPubMed Central
JournalAdv Sci (Weinh)
AuthorsJori, Chandrashekhar, Shaney Rehman, Ahmed, Lamba, Taruna +8 more
Indexed viaPubMed Central
Source typeResearch repository record
PublishedJul 20, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Targeted β‐Glucan‐Veiled Oral Apremilast Nanotherapy Modulates Key Dysbiosis‐Associated Gut Microbiota and Alleviates Ulcerative Colitis‐Associated Anxiety, Depression, and Neuropsychiatric Behaviors
The study describes a new oral nanotherapy that delivered apremilast to the inflamed colon in mice and reportedly reduced gut inflammation and behaviors resembling anxiety/depression—suggesting a combined...
Targeted β-Glucan-Veiled Oral Apremilast Nanotherapy Modulates Key Dysbiosis-Associated Gut Microbiota and Alleviates Ulcerative Colitis-Associated Anxiety, Depression, and Neuropsychiatric Behaviors.
People with IBD often have higher rates of anxiety and depression; this study suggests an experimental oral nanotherapy carrying apremilast might treat both gut inflammation and related neuropsychiatric symptoms in...
Postbiotic Nagqu4580 Attenuates Ulcerative Colitis and Suppresses Ferroptosis in Association with the Microbiota-Tryptophan-AhR/Nrf2 Axis.
This preclinical study suggests a fermented postbiotic product may protect the colon in a mouse model of ulcerative colitis by altering the microbiome and tryptophan metabolites and by reducing ferroptotic cell death....